Brief: Harrow Health Inc Says CMS Approved Transitional Pass-Through Reimbursement Status For IHEEZO 3%
13/03/2023 11:40
March 13 (Reuters) - Harrow Health Inc HROW.O :
* HARROW HEALTH INC - CMS APPROVED TRANSITIONAL PASS-THROUGH
REIMBURSEMENT STATUS FOR IHEEZO 3%
Source text for Eikon: ID:nBw8wDMTya
Further company coverage: HROW.O
Recent news on Harrow
See all newsHarrow, Inc. reports results for the quarter ended June 30 - Earnings Summary
Harrow Q2 revenue slightly beats estimates
Viatris raises annual profit forecast on branded drug strength
Brief: Harrow Re-Launches Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% For Vernal Keratoconjunctivitis, Addressing Significant Unmet Need In Pediatric Eyecare
Harrow Q1 revenue misses analyst estimates